Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy-Reference-Cited by-同舟云学术

Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy

Published:2022-06 Issue: Volume:60 Page:101496
ISSN:2212-8778
Container-title:Molecular Metabolism
language:en
Short-container-title:Molecular Metabolism

Author:

Mascaraque-Checa Marta^ORCID,Gallego-Rentero María,Nicolás-Morala Jimena,Portillo-Esnaola Mikel,Cuezva José M.,González Salvador,Gilaberte Yolanda^ORCID,Juarranz Ángeles

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology

Reference94 articles.

1. Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease;Burton;American Journal of Clinical Dermatology,2016

2. Non-melanoma skin cancer and risk of all-cause and cancer-related mortality: a systematic review;Barton;Archives of Dermatology,2017

3. The epidemiology of skin cancer;Diepgen;British Journal of Dermatology,2002

4. Squamous cell carcinoma of the skin;Rudolph;Plastic and Reconstructive Surgery,2004

5. Melanotic and non-melanotic malignancies of the face and external ear – a review of current treatment concepts and future options;Kolk;Cancer Treatment Reviews,2014

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reprogramming of glucose metabolism: The hallmark of malignant transformation and target for advanced diagnostics and treatments;Biomedicine & Pharmacotherapy;2024-09

2. Targeting Metabolic–Redox Nexus to Regulate Drug Resistance: From Mechanism to Tumor Therapy;Antioxidants;2024-07-10

3. The use of photodynamic therapy in medical practice;Frontiers in Oncology;2024-05-08

4. Metabolic Reprogramming of Anti-cancer T Cells: Targeting AMPK and PPAR to Optimize Cancer Immunotherapy;Indian Journal of Clinical Biochemistry;2024-01-08

5. The m-TORC1 inhibitor Sirolimus increases the effectiveness of Photodynamic therapy in the treatment of cutaneous Squamous Cell Carcinoma, impairing NRF2 antioxidant signaling;International Journal of Biological Sciences;2024